Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer

2024/03/05 by Honghu Zhang, Lin Qi, Yi Cai +1
Medicine · Neuroscience · #Neuropeptides and Animal Physiology #Peptidase Inhibition and Analysis #Prostate Cancer Treatment and Research

paper · pdf · doi:10.1080/07853890.2024.2320301

openalex publication_date 2024/03/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

In conclusion, this review highlights the emerging role of GRPR in prostate cancer diagnosis and treatment. Moreover, the integration of radionuclide-targeted therapy with GRPR antagonists introduces an innovative therapeutic approach that holds promise for improving outcomes in individuals dealing with prostate cancer. The potential prognostic value of GRPR in assessing the disease's progression adds another dimension to its clinical significance in the realm of urology.

Related

• Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin
• GLP1 receptor agonism alters growth and therapeutic response in prostate cancer
• Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging
• Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value
• Therapeutic Strategies to Target the Androgen Receptor